Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Bendell; S. Ulahannan; M. Koczywas; J. Brahmer; A. Capasso; S. G. Eckhardt; M. Gordon; C. McCoach; M. Nagasaka; K. Ng; J. Pacheco; J. Riess; A. Spira; C. Steuer; R. Dua; S. Chittivelu; S. Masciari; Z. Wang; X. Wang; S. H. Ou

doi:10.1016/S0959-8049(20)31089-3

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Bendell, S. Ulahannan, M. Koczywas, J. Brahmer, A. Capasso, S. G. Eckhardt, M. Gordon, C. McCoach, M. Nagasaka, K. Ng, J. Pacheco, J. Riess, A. Spira, C. Steuer, R. Dua, S. Chittivelu, S. Masciari, Z. Wang, X. Wang, S. H. Ou

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	S8-S9
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)31089-3
State	Published - Oct 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(20)31089-3

Cite this

Bendell, J., Ulahannan, S., Koczywas, M., Brahmer, J., Capasso, A., Eckhardt, S. G., Gordon, M., McCoach, C., Nagasaka, M., Ng, K., Pacheco, J., Riess, J., Spira, A., Steuer, C., Dua, R., Chittivelu, S., Masciari, S., Wang, Z., Wang, X., & Ou, S. H. (2020). Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. European Journal of Cancer, 138, S8-S9. https://doi.org/10.1016/S0959-8049(20)31089-3

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. / Bendell, J.; Ulahannan, S.; Koczywas, M.; Brahmer, J.; Capasso, A.; Eckhardt, S. G.; Gordon, M.; McCoach, C.; Nagasaka, M.; Ng, K.; Pacheco, J.; Riess, J.; Spira, A.; Steuer, C.; Dua, R.; Chittivelu, S.; Masciari, S.; Wang, Z.; Wang, X.; Ou, S. H.

In: European Journal of Cancer, Vol. 138, 10.2020, p. S8-S9.

Research output: Contribution to journal › Article › peer-review

Bendell, J, Ulahannan, S, Koczywas, M, Brahmer, J, Capasso, A, Eckhardt, SG, Gordon, M, McCoach, C, Nagasaka, M, Ng, K, Pacheco, J, Riess, J, Spira, A, Steuer, C, Dua, R, Chittivelu, S, Masciari, S, Wang, Z, Wang, X & Ou, SH 2020, 'Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling', European Journal of Cancer, vol. 138, pp. S8-S9. https://doi.org/10.1016/S0959-8049(20)31089-3

Bendell J, Ulahannan S, Koczywas M, Brahmer J, Capasso A, Eckhardt SG et al. Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. European Journal of Cancer. 2020 Oct;138:S8-S9. https://doi.org/10.1016/S0959-8049(20)31089-3

Bendell, J. ; Ulahannan, S. ; Koczywas, M. ; Brahmer, J. ; Capasso, A. ; Eckhardt, S. G. ; Gordon, M. ; McCoach, C. ; Nagasaka, M. ; Ng, K. ; Pacheco, J. ; Riess, J. ; Spira, A. ; Steuer, C. ; Dua, R. ; Chittivelu, S. ; Masciari, S. ; Wang, Z. ; Wang, X. ; Ou, S. H. / Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. In: European Journal of Cancer. 2020 ; Vol. 138. pp. S8-S9.

@article{dee09a266fa84f9abe0c296256bca6fd,

title = "Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling",

author = "J. Bendell and S. Ulahannan and M. Koczywas and J. Brahmer and A. Capasso and Eckhardt, {S. G.} and M. Gordon and C. McCoach and M. Nagasaka and K. Ng and J. Pacheco and J. Riess and A. Spira and C. Steuer and R. Dua and S. Chittivelu and S. Masciari and Z. Wang and X. Wang and Ou, {S. H.}",

note = "Funding Information: J. Pacheco: Research Grant (Institution): Pfizer. ",

year = "2020",

month = oct,

doi = "10.1016/S0959-8049(20)31089-3",

language = "English (US)",

volume = "138",

pages = "S8--S9",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

AU - Bendell, J.

AU - Ulahannan, S.

AU - Koczywas, M.

AU - Brahmer, J.

AU - Capasso, A.

AU - Eckhardt, S. G.

AU - Gordon, M.

AU - McCoach, C.

AU - Nagasaka, M.

AU - Ng, K.

AU - Pacheco, J.

AU - Riess, J.

AU - Spira, A.

AU - Steuer, C.

AU - Dua, R.

AU - Chittivelu, S.

AU - Masciari, S.

AU - Wang, Z.

AU - Wang, X.

AU - Ou, S. H.

N1 - Funding Information: J. Pacheco: Research Grant (Institution): Pfizer.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85093980863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093980863&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(20)31089-3

DO - 10.1016/S0959-8049(20)31089-3

M3 - Article

AN - SCOPUS:85093980863

VL - 138

SP - S8-S9

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -